Related Experiment Video
Updated: Feb 5, 2026

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
Published on: July 6, 2019
Direct factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2/NF-κB signaling
Meng Shi1,2, Linlin Wang3,2, Jian Zhou3,2
1Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University Shanghai, China.
Abstract:
The role of coagulation in acute lung injury (ALI) remains unclear. As factor Xa-dependent protease-activated receptor 2 (PAR-2) is reported to be an important target in blood coagulation and other processes, an inhibitor of factor Xa, rivaroxaban, was tested in vivo in C57BL/6 mice with ALI induced by intratracheal injections of lipopolysaccharide (LPS) and in vitro in LPS-stimulated human umbilical vein endothelial cells. Plasma concentrations and coagulation indices were measured in mice fed normal chow or chow containing rivaroxaban (0.2 or 0.4 mg/g) for 10 days. The rivaroxaban-treated mice had significantly reduced neutrophil sequestration with preservation of the lung tissue architecture compared with that in the untreated controls. The levels of tumor necrosis factor alpha, interleukin 1 beta, and interleukin 6, as well as total protein and Evans blue concentrations, were all significantly reduced in bronchoalveolar lavage fluid from mice treated with rivaroxaban. Rivaroxaban treatment also ameliorated the LPS-induced PAR-2 increase and nuclear factor kappa B (NF-κB) activation. In vitro, cells treated with rivaroxaban had higher cell viability with an attenuation of LPS-induced increases in membrane permeability and proinflammatory cytokine levels, as well as reduced apoptosis. Furthermore, rivaroxaban inhibited the phosphorylation of TAK1 and p65. These data show that rivaroxaban attenuates ALI and inflammation by inhibiting the PAR-2/NF-κB signaling pathway.
Insights
Rivaroxaban, a factor Xa inhibitor, reduces inflammation and lung injury in acute lung injury (ALI) models. It works by inhibiting the protease-activated receptor 2 (PAR-2) and nuclear factor kappa B (NF-κB) signaling pathway.
Area of Science:
- Coagulation and Inflammation Research
- Pulmonary Medicine
- Pharmacology
Background:
- The role of blood coagulation in acute lung injury (ALI) is not fully understood.
- Protease-activated receptor 2 (PAR-2), a target in coagulation, is implicated in inflammatory processes.
- Factor Xa inhibitors, like rivaroxaban, may offer therapeutic potential for ALI.
Purpose of the Study:
- To investigate the efficacy of rivaroxaban in an in vivo mouse model of ALI.
- To examine the effects of rivaroxaban on inflammatory markers and cell signaling pathways in vitro.
- To determine if rivaroxaban attenuates ALI by inhibiting the PAR-2/NF-κB pathway.
Main Methods:
- Acute lung injury (ALI) was induced in C57BL/6 mice using lipopolysaccharide (LPS).
- Mice were treated with rivaroxaban (0.2 or 0.4 mg/g) orally for 10 days.
- In vitro studies used LPS-stimulated human umbilical vein endothelial cells treated with rivaroxaban.
- Measurements included plasma coagulation indices, lung histology, bronchoalveolar lavage fluid analysis, and Western blotting for signaling proteins.
Main Results:
- Rivaroxaban treatment significantly reduced neutrophil sequestration and preserved lung tissue architecture in ALI mice.
- Levels of inflammatory cytokines (TNF-α, IL-1β, IL-6), protein, and Evans blue were decreased in bronchoalveolar lavage fluid.
- Rivaroxaban ameliorated LPS-induced increases in PAR-2 expression and NF-κB activation.
- In vitro, rivaroxaban improved cell viability, reduced membrane permeability, decreased cytokine release, and inhibited apoptosis.
- Rivaroxaban inhibited the phosphorylation of TAK1 and p65, key components of the NF-κB pathway.
Conclusions:
- Rivaroxaban effectively attenuates acute lung injury (ALI) in a mouse model.
- The anti-inflammatory effects of rivaroxaban are mediated through the inhibition of the PAR-2/NF-κB signaling pathway.
- Rivaroxaban demonstrates potential as a therapeutic agent for ALI by targeting coagulation and inflammation crosstalk.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Direct Motor Pathways
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

